Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States, and more than half of advanced AMD patients have the wet (exudative, neovascular) form of the disease. Currently available therapies targeting vascular endothelial growth factor (VEGF) have been shown to maintain and even improve visual acuity in wet AMD patients, including Roche / Genentech’s Avastin (bevacizumab), Roche / Genentech’s Lucentis (ranibizumab), Regeneron’s Eylea (aflibercept), and Novartis’s Beovu (brolucizumab). Using national, longitudinal, patient-level U.S. claims data, this report examines recent trends in the management of wet AMD both for newly diagnosed patients and patients filling a prescription for a key therapy in the first six months of 2021.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Roche / Genentech, Regeneron, Novartis
Key drugs: Avastin, Lucentis, Eylea, Beovu
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.